🇺🇸 FDA
Patent

US 8563614

Use of treprostinil to treat neuropathic diabetic foot ulcers

granted A61KA61K31/557A61P

Quick answer

US patent 8563614 (Use of treprostinil to treat neuropathic diabetic foot ulcers) held by United Therapeutics Corporation expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/557, A61P, A61P17/02, A61P29/00